Page last updated: 2024-08-25

bendamustine hydrochloride and Shingles

bendamustine hydrochloride has been researched along with Shingles in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's2 (50.00)2.80

Authors

AuthorsStudies
Alderuccio, JP; Alexander, JS; Alpert, AB; Arcaini, L; Argnani, L; Ayyappan, S; Beaven, AW; Castillo, JJ; Cencini, E; Chowdhury, SM; Edwards, D; Epperla, N; Friedberg, JW; Gaballa, S; Herrera, AF; Hess, B; Kahl, BS; Kamdar, M; Kim, SH; Kwon, D; Link, BK; Logothetis, CN; Lossos, IS; Luminari, S; Martin, P; Olszewski, AJ; Reis, IM; Saba, R; Sandoval-Sus, J; Shouse, G; Spina, M; Stefanovic, A; Torka, P; Vargas, F; Voorhees, TJ; Watkins, MP; Zhao, W; Zinzani, PL1
Kashiwagi, M; Kawai, R; Kawashiri, T; Shimizu, T; Uchida, M; Uesawa, Y1
Kempf, W; Mitteldorf, C; Tronnier, M; Wollert, E1
Hamdan, A; Joyce, RM; Tzachanis, D; Uhlmann, EJ1

Other Studies

4 other study(ies) available for bendamustine hydrochloride and Shingles

ArticleYear
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.
    Blood advances, 2022, 04-12, Volume: 6, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Herpes Zoster; Humans; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Rituximab; Young Adult

2022
Time to Onset of Bendamustine-associated Skin Damage Using the Spontaneous Reporting System.
    Anticancer research, 2022, Volume: 42, Issue:5

    Topics: Adverse Drug Reaction Reporting Systems; Bendamustine Hydrochloride; Drug-Related Side Effects and Adverse Reactions; Exanthema; Herpes Zoster; Humans; Quality of Life

2022
Generalized maculopapular and vesicular rash.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2018, Volume: 16, Issue:2

    Topics: Acyclovir; Aged; Bendamustine Hydrochloride; Drug Eruptions; Epidermis; Herpes Zoster; Humans; Immunoblastic Lymphadenopathy; Keratinocytes; Lymphocytes; Lymphoma, T-Cell; Male; Programmed Cell Death 1 Receptor; Skin

2018
Successful treatment of refractory Guillain-Barré syndrome with alemtuzumab in a patient with chronic lymphocytic leukemia.
    Acta haematologica, 2014, Volume: 132, Issue:2

    Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoantigens; Bendamustine Hydrochloride; CD52 Antigen; Combined Modality Therapy; Consciousness Disorders; Gangliosides; Glycoproteins; Guillain-Barre Syndrome; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunoglobulins, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Miller Fisher Syndrome; Nitrogen Mustard Compounds; Plasmapheresis; Remission Induction; Rituximab; Virus Activation

2014